News-Media – BIT Pharma

RECENT

News-Media

Available resources, including latest press releases and information on our company and pipeline

The recent published results of the ISAT-2 study draw a different view on the future of open microsurgical intervention for aSAH and on the therapeutic implications of its treatment with NicaPlant

18. January 2025

The recent published results of the ISAT-2 study draw a different view on the future of open microsurgical intervention for aSAH and on the therapeutic implications of its treatment with NicaPlant

BIT Pharma announces the publication of an original investigation with the results of a randomized clinical trial with NicaPlant (Nicardipine Release Implants) for the prevention of vasospasm after Aneurysmal Subarachnoid Hemorrhage in JAMA Neurology.

20. August 2024

BIT Pharma announces the publication of an original investigation with the results of a randomized clinical trial with NicaPlant (Nicardipine Release Implants) for the prevention of vasospasm after Aneurysmal Subarachnoid Hemorrhage in JAMA Neurology.

Phase 2a results published in Brain and Spine

4. October 2023

Phase 2a results published in Brain and Spine

Phase 2 data with NicaPlant ® in aneurysmal subarachnoid haemorrhage patients will be presented at the XXVI Congress of Spanish Society of Neurosurgery (SENEC)

22. May 2023

Phase 2 data with NicaPlant ® in aneurysmal subarachnoid haemorrhage patients will be presented at the XXVI Congress of Spanish Society of Neurosurgery (SENEC)

Augxano and BIT Pharma enter into an Agreement for Commercialization Support in Asia

14. December 2022

Augxano and BIT Pharma enter into an Agreement for Commercialization Support in Asia

ASPEN And BIT PHARMA Enter Into An Exclusive Agreement For A Nicardipine-Based Intracerebral Implant

29. October 2022

ASPEN And BIT PHARMA Enter Into An Exclusive Agreement For A Nicardipine-Based Intracerebral Implant

European Medicines Agency Grants PRIME Designation to BIT Pharma’s NicaPlant® for Treatment of Non-traumatic Subarachnoid Haemorrhage in Patients undergoing Surgery.

19. October 2022

European Medicines Agency Grants PRIME Designation to BIT Pharma’s NicaPlant® for Treatment of Non-traumatic Subarachnoid Haemorrhage in Patients undergoing Surgery.

BIT Pharma is Honoured to Work with a World’s Top Neurosurgery Department

10. October 2022

BIT Pharma is Honoured to Work with a World’s Top Neurosurgery Department

BIT Pharma Announces the Presentation of NicaPlant® Phase 2 Results at International Conferences

31. August 2022

BIT Pharma Announces the Presentation of NicaPlant® Phase 2 Results at International Conferences

BIT Pharma Announces Positive Phase 2b Study Results for NicaPlant® in Aneurysmal Subarachnoid Heamorrhage patients (aSAH) undergoing aneurysm clipping.

1. July 2022

BIT Pharma Announces Positive Phase 2b Study Results for NicaPlant® in Aneurysmal Subarachnoid Heamorrhage patients (aSAH) undergoing aneurysm clipping.

Contact Us

Send us an email for further inquiry.